NCT03131037View on ClinicalTrials.gov

Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 4, 2017

Primary Completion Date

December 1, 2021

Study Completion Date

September 20, 2023

Conditions
Lung Cancer
Interventions
BIOLOGICAL

CAN-2409 + valacyclovir

CAN-2409 will be administered intratumorally followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each injection.

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors
All Listed Sponsors
collaborator

University of Pennsylvania

OTHER

lead

Candel Therapeutics, Inc.

INDUSTRY